EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

A Minimum 3‐Year Follow‐Up of Nivolumab‐Plus‐Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J‐ ENCORE Study

Shuzo Hamamoto iD, Masahiro Nozawa, Suguru Shirotake, Tomokazu Sazuka iD, Kazuyuki Numakura, Atsushi Mizokami iD, Tsunenori Kondo, Sei Naito iD, Takashige Abe iD, Kojiro Ohba iD, Go Kimura, Masayoshi Nagata und 3 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70400 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Shuzo Hamamoto und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Nivolumab, Kidney Neoplasms, Ipilimumab. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb, Ono Pharmaceutical, Ono Pharmaceutical Co. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The J‐ENCORE study is a Japanese multicenter, prospective observational study involving patients with advanced or metastatic renal cell carcinoma treated with nivolumab‐plus‐ipilimumab combination as first‐line treatment. Interim 1‐ and 2‐year reports demonstrated efficacy and safety comparable to those of the CheckMate 214 trial, with sustained effects after nivolumab‐plus‐ipilimumab discontinuation, and explored outcome‐associated factors. This final analysis of a minimum 3‐year observation summarized long‐term outcomes, including real‐world second progression‐free survival and overall survival, and explored outcome‐associated factors.

Methods

Real‐world objective response rate, response duration, real‐world progression‐free survival, overall survival, treatment‐related adverse events, and real‐world second progression‐free survival were evaluated. Outcome‐associated factors were explored.

Results

The study included 274 patients (68.2% aged ≥ 65 years; 42.0%, poor risk) from 37 sites, with a median follow‐up of 47.4 (range, 36.5–59.0) months. Real‐world objective response rate was 38.4%, with 30.5% maintaining ≥ 36 months response duration. Median real‐world progression‐free survival and second progression‐free survival were 9.7 and 30.1 months, respectively, and 60.2% of patients survived for ≥ 36 months. Treatment‐related adverse events of any grade, grade 3/4, and grade 5 occurred in 78.5%, 43.1%, and 1.1% of patients, respectively. No new treatment‐related adverse events or increased frequencies were reported since the previous interim analyses. Multivariable analyses identified associations between overall survival and age, lactate dehydrogenase levels, and C‐reactive protein levels, with favorable prognosis in patients with none or one of these factors.

Conclusions

We demonstrated long‐term real‐world outcomes of nivolumab‐plus‐ipilimumab. Our findings support prescriptions of nivolumab‐plus‐ipilimumab in real‐world clinical practice. Trail Registration UMIN Clinical Trials Registry: UMIN000036772 and ClinicalTrials.gov : NCT04043975

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellNivolumabKidney NeoplasmsIpilimumabAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleAgedJapanProspective StudiesMaleProgression-Free SurvivalFollow-Up StudiesMiddle AgedAged, 80 and overAdultTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

Japanipilimumabnivolumabprospective studyrenal cell carcinoma

Substanzen

NivolumabIpilimumab

Autor:innen und Institutionen

  • Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Urology, Kindai University Faculty of Medicine, Sakai, Japan.
  • Department of Urology, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan.
  • Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
  • Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.

ORCID-Profile: Shuzo Hamamoto, Tomokazu Sazuka, Atsushi Mizokami, Sei Naito, Takashige Abe, Kojiro Ohba, Hirotsugu Uemura

Förderung

  • Bristol Myers Squibb
  • Ono Pharmaceutical
  • Ono Pharmaceutical Co. Ltd.
  • Bristol-Myers Squibb
  • Bristol-Myers Squibb Canada

Zitieren

APA

Hamamoto, S., Nozawa, M., Shirotake, S., Sazuka, T., Numakura, K., Mizokami, A., Kondo, T., Naito, S., Abe, T., Ohba, K., Kimura, G., Nagata, M., Onodera, S., Yamaguchi, K., & Uemura, H. (2026). A Minimum 3‐Year Follow‐Up of Nivolumab‐Plus‐Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J‐ ENCORE Study. International Journal of Urology. https://doi.org/10.1111/iju.70400

Vancouver

Hamamoto S, Nozawa M, Shirotake S, Sazuka T, Numakura K, Mizokami A, et al. A Minimum 3‐Year Follow‐Up of Nivolumab‐Plus‐Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J‐ ENCORE Study. International Journal of Urology. 2026. doi:10.1111/iju.70400

BibTeX
@article{Hamamoto2026,
  author = {Hamamoto, Shuzo and Nozawa, Masahiro and Shirotake, Suguru and Sazuka, Tomokazu and Numakura, Kazuyuki and Mizokami, Atsushi and Kondo, Tsunenori and Naito, Sei and Abe, Takashige and Ohba, Kojiro and Kimura, Go and Nagata, Masayoshi and Onodera, Shunta and Yamaguchi, Katsumi and Uemura, Hirotsugu},
  title = {A Minimum 3‐Year Follow‐Up of Nivolumab‐Plus‐Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J‐ ENCORE Study},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70400}
}
Kostenlos starten →